Analysed SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) News Sources
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
21-04-2026
yahoo.com
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
04-05-2026
yahoo.com
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
01-06-2026
yahoo.com
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
12-06-2026
yahoo.com
What is the current price of SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS)?
The current price of SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) is $0.
SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) since the previous trading day is $None.
SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) since the previous trading day is None%.
What is the most recent average sentiment score for SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS)?
The most recent average sentiment score for SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) is 71 out of 100.
What is the most recent average sentiment for SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS)?
The most recent sentiment for SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS) is .
SEC-8K** Filing Available For SIMCERE PHARMACEUTICAL GROUP (SMHGF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.